Hongjun Li
- Biomaterials top 0.2%
- Nanoparticle-Based Drug Delivery 20
- Pharmaceutical Science top 0.5%
- Biomedical Engineering top 0.5%
- Nanoplatforms for cancer theranostics 20
- Immunology top 2%
- Immunotherapy and Immune Responses 15
- Immune cells in cancer 9
- Molecular Biology top 2%
- RNA Interference and Gene Delivery 14
-
- CAR-T cell therapy research 17
-
- Virus-based gene therapy research 11
-
- Cancer Research and Treatments 8
- Partner nations
- ChinaUnited StatesSingapore
In The Last Decade
Hongjun Li
146 papers receiving 6.8k citations
Hit Papers
Peers
Comparison fields: 5 of 148
- Biomaterials 2.1k
- Pharmaceutical Science 506
- Biomedical Engineering 3.2k
- Immunology 1.1k
- Molecular Biology 2.5k
Countries citing papers authored by Hongjun Li
This map shows the geographic impact of Hongjun Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongjun Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongjun Li more than expected).
Fields of papers citing papers by Hongjun Li
This network shows the impact of papers produced by Hongjun Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongjun Li. The network helps show where Hongjun Li may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hongjun Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2024 | 13 | |
| 3 | 2024 | 18 | |
| 4 | Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironmentbreakdown → | 2024 | 68 |
| 5 | 2023 | 21 | |
| 6 | 2023 | 14 | |
| 7 | 2023 | 62 | |
| 8 | 2023 | 4 | |
| 9 | 2023 | 9 | |
| 10 | 2023 | 13 | |
| 11 | 2023 | 37 | |
| 12 | 2022 | 9 | |
| 13 | 2022 | 45 | |
| 14 | 2021 | 62 | |
| 15 | Tailoring Materials for Modulation of Macrophage Fatebreakdown → | 2021 | 298 |
| 16 | 2020 | 95 | |
| 17 | 2018 | 89 | |
| 18 | 2015 | 87 | |
| 19 | 2014 | 20 | |
| 20 | 2004 | 1 |
About Hongjun Li
Hongjun Li is a scholar working on Biomaterials, Immunology and Oncology, having authored 153 papers that have together received 6.8k indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (20 papers), Nanoparticle-Based Drug Delivery (20 papers), CAR-T cell therapy research (17 papers), Immunotherapy and Immune Responses (15 papers), RNA Interference and Gene Delivery (14 papers), Virus-based gene therapy research (11 papers), Immune cells in cancer (9 papers) and Cancer Research and Treatments (8 papers). The work is most often cited by research in Biomaterials (2.1k citations), Pharmaceutical Science (506 citations) and Biomedical Engineering (3.2k citations). Hongjun Li has collaborated with scholars based in China, United States and Singapore. Frequent co-authors include Jun Wang, Zhen Gu, Jin‐Zhi Du, Xiao‐Jiao Du, Xianzhu Yang, Cong‐Fei Xu, Song Shen, Shuming Nie, Di Wen and Guojun Chen. Their work appears in journals such as Biomaterials, ACS Nano, Advanced Materials, Nano Today and Science Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.